Quest Diagnostics Incorporated
MADISON, New Jersey and CYPRESS, California, November 15, 2011 -
- With the new Focus Diagnostics' Simplexa molecular test on the 3M™ Integrated Cycler, the company now offers one of the most comprehensive molecular transplant-testing menus in Europe
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test kit on the 3M™ Integrated Cycler for distribution to approximately 35 countries in Europe.
CYPRESS, California and MADISON, New Jersey, November 3, 2011 -
- Focus Diagnostics product eliminates nucleic-acid sample extraction with proprietary technology, for faster testing
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the CE mark and European availability of the Simplexa Flu A/B & RSV Direct test on the 3M™ Integrated Cycler.
D"SSELDORF, Germany, November 18 - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider
of diagnostic testing, information and services, today announced that the
Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics
business has been CE marked and is now available as a test kit for
distribution to approximately 35 countries in Europe.
